Pluripotent Stem Cell

Pluripotent Stem Cell possesses the remarkable ability to differentiate into virtually any cell type in the human body, offering unprecedented opportunities for regenerative medicine, disease modelling, and drug discovery. These cells maintain self-renewal capacity while retaining developmental flexibility, representing a powerful biological resource for addressing previously untreatable conditions.

Two primary types drive current research: embryonic stem cells derived from early-stage embryos, and induced pluripotent stem cells created by reprogramming adult cells. iPSC technology recognised with the 2012 Nobel Prize has revolutionised the field by enabling patient-specific cell generation without embryonic sources. The biopharmaceutical sector leverages pluripotent stem cells for multiple applications, including cell therapies targeting conditions like macular degeneration and Parkinson's disease, and drug developers utilise pluripotent stem cell-derived cardiomyocytes and hepatocytes to predict cardiotoxicity and liver toxicity during preclinical safety testing. Regulatory frameworks continue evolving to address pluripotent stem cell therapies' unique characteristics, ensuring these transformative technologies reach patients safely and effectively while maintaining appropriate quality and safety standards.